Pages that link to "Item:Q5424959"
From MaRDI portal
The following pages link to Uses and limitations of randomization-based efficacy estimators (Q5424959):
Displaying 10 items.
- Instrumental variable estimation of early treatment effect in randomized screening trials (Q2074076) (← links)
- A structural mean model to allow for noncompliance in a randomized trial comparing 2 active treatments (Q3303668) (← links)
- Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial (Q3303671) (← links)
- A Comparison of Methods for Estimating the Causal Effect of a Treatment in Randomized Clinical Trials Subject to Noncompliance (Q3637022) (← links)
- Simple maximum likelihood estimates of efficacy in randomized trials and before-and-after studies, with implications for meta-analysis (Q5424960) (← links)
- Why There's No Cause to Randomize (Q5426529) (← links)
- Uses and limitations of randomization-based efficacy estimators (Q5442623) (← links)
- Simple maximum likelihood estimates of efficacy in randomized trials and before-and-after studies, with implications for meta-analysis (Q5442624) (← links)
- There Is Cause to Randomize (Q5883926) (← links)
- Assessing the ratio of means as a causal estimand in clinical endpoint bioequivalence studies in the presence of intercurrent events (Q6627246) (← links)
